Stock comparison
Edwards Lifesciences
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EW
Edwards Lifesciences
Market cap
$49.39B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EW | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 75B | IDXX |
| Benjamin Graham | 89A | 80A | EW |
| Philip Fisher | 62C | 75B | IDXX |
| Peter Lynch | 26F | 71B | IDXX |
| Joel Greenblatt | 54C | 83C | IDXX |
| Charlie Munger | 71C | 87A | IDXX |
| Terry Smith | 70B | 84A | IDXX |
Side-by-side metrics
| Metric | EW | IDXX |
|---|---|---|
| Market cap | $49.39B | $44.12B |
| P/E (TTM) | 43.2x | 39.0x |
| EV/EBIT | 27.6x | 31.6x |
| ROIC (TTM) | 12.06% | 40.66% |
| Gross margin | 78.01% | 62.05% |
| Net margin | 17.34% | 24.63% |
| Revenue CAGR 5y | 3.77% | 7.56% |
| EPS CAGR 5y | -6.52% | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EW leads on
- Debt / Equity0.1xvs 0.7x+90%
- Gross margin78.01%vs 62.05%+20%
- EV/EBIT27.6xvs 31.6x+13%
- Market cap$49.39Bvs $44.12B+11%
IDXX leads on
- EPS CAGR 5y10.79%vs -6.52%+160%
- ROIC (TTM)40.66%vs 12.06%+70%
- Revenue CAGR 5y7.56%vs 3.77%+50%
- Net margin24.63%vs 17.34%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.